⚠️
Important: VAERS reports alone cannot determine if a vaccine caused an adverse event. Reports may contain incomplete, inaccurate, or unverified information. Correlation does not equal causation.
Injection site cellulitis
4,236 total reports7.1% serious outcomes
Share
4,236
Total Reports
2
Deaths
297
Hospitalizations
7.1
Severity Rate
% serious outcomes
About Injection site cellulitis Reports
Injection site cellulitis has been reported 4,236 times in VAERS from 1990 to 2026.
Of these reports, 2 were associated with death (0.05%) and 297 involved hospitalization.
The overall serious outcome rate (death or hospitalization) for reports mentioning Injection site cellulitis is 7.1%.
Understanding Injection site cellulitis in VAERS
•Temporal association only: These reports show Injection site cellulitis occurred after vaccination, not necessarily because of vaccination.
•Background rates matter: Many symptoms occur naturally at baseline rates in the population, unrelated to vaccination.
•Reporting variability: Medical terminology may be used differently by various healthcare providers and over time.
•Investigation needed: High-frequency reports may trigger further epidemiological studies to determine causation.
What This Data Shows
Most Associated Vaccines: The vaccines most frequently mentioned in reports with Injection site cellulitis. This may reflect usage patterns, not causation.
Severity Patterns: The percentage of reports that involve serious outcomes can help prioritize safety investigations.
Reporting Trends: Changes in reporting frequency over time may reflect increased awareness, media attention, or actual safety signals.
Most Associated Vaccines
1. PPV1,198
2. FLU3665
3. VARCEL654
4. VARZOS541
5. COVID19527
6. TDAP435
7. MMR372
8. DTAPIPV348
9. DTAP347
10. PNC13301
Quick Facts
Reports:4,236
Deaths:2
Hospitalizations:297
Mortality Rate:0.05%
Severity Rate:7.1%
Related Analysis
Explore Further
Data Source
This data comes from the Vaccine Adverse Event Reporting System (VAERS), jointly managed by CDC and FDA.